What is the maximum recommended dose of spironolactone for a transgender woman using it as the anti‑androgen in feminizing hormone therapy?

Maximum Spironolactone Dose for Transgender Women

For transgender women using spironolactone as an anti-androgen in feminizing hormone therapy, doses typically range from 100-200 mg daily, though the FDA-approved maximum dose is 400 mg/day for primary aldosteronism. 1

Dosing Framework for Feminizing Hormone Therapy

Standard Dosing Range

• Starting dose: 100 mg daily 2, 3
• Typical maintenance: 100-200 mg daily
• Maximum FDA-approved dose: 400 mg/day (for primary aldosteronism indication) 4, 1

The evidence shows that 100 mg daily is commonly used in clinical trials for transgender women 2, 3. Historical data from 1989 demonstrated effective testosterone suppression with doses of 200-600 mg/day in transgender women, achieving female-range testosterone levels 5. However, modern practice typically uses lower doses (100-200 mg daily) in combination with estradiol.

Efficacy Considerations

Spironolactone is less potent than cyproterone acetate for testosterone suppression. A 2021 randomized controlled trial found that only 19% of transgender women on spironolactone 100 mg/day achieved female-range testosterone (<50 ng/dL) at 12 weeks, compared to 90% with cyproterone acetate 25 mg/day 3. A 2024 trial confirmed no significant difference in breast development between the two agents at 6 months 2.

Practical Dosing Algorithm

1. Initial dose: Start at 100 mg daily with estradiol therapy
2. Monitor at 4-8 weeks: Check testosterone, potassium, and renal function
3. Titration: If testosterone remains elevated and potassium/renal function are normal, may increase to 200 mg daily
4. Higher doses: Doses above 200 mg/day can be considered if:
   • Testosterone suppression remains inadequate
   • Potassium remains <5.0 mEq/L
   • eGFR >50 mL/min/1.73 m²
   • Patient tolerates current dose without adverse effects

Critical Safety Monitoring

Hyperkalemia Risk

Hyperkalemia is the most serious adverse effect and requires vigilant monitoring. 6, 7, 8

• Baseline requirements: Potassium ≤5.0 mEq/L, eGFR >30 mL/min/1.73 m² 8, 1
• Monitoring schedule: Check potassium and renal function at 3 days, 1 week, then monthly for 3 months, then every 3 months 9, 8
• Action thresholds:
  • Potassium >5.5 mEq/L: Reduce dose by 50%
  • Potassium ≥6.0 mEq/L: Stop immediately 6, 7

Renal Function Considerations

• eGFR 30-50 mL/min/1.73 m²: Consider starting at 25 mg every other day 1
• eGFR <30 mL/min/1.73 m²: Avoid use 4

Advantages in Transgender Women

Unlike in cisgender men, the anti-androgenic side effects of spironolactone (gynecomastia, decreased libido) are actually desired therapeutic effects in transgender women. 10 This makes spironolactone particularly suitable for this population, as the side effects that limit use in other contexts become beneficial.

Key Differences from Other Indications

The 2024 primary aldosteronism guidelines cite a maximum of 400 mg/day 4, and the FDA label confirms this maximum 1. However, for heart failure, the evidence-based target is only 50 mg daily 6, 7. For transgender women, the appropriate maximum falls between these extremes—typically 200 mg daily, with 400 mg/day as an absolute ceiling in select cases.

Common Pitfalls to Avoid

1. Inadequate monitoring: Population-based studies show hyperkalemia rates of 24% in real-world practice versus 2% in clinical trials 9, 8
2. Combining with ACE inhibitors/ARBs: Avoid triple therapy (ACEI + ARB + spironolactone) due to hyperkalemia risk 8
3. NSAIDs: Counsel patients to avoid NSAIDs and COX-2 inhibitors, which worsen renal function and hyperkalemia risk 9, 8
4. Pregnancy: Spironolactone causes feminization of male fetuses and must be avoided in pregnancy 1